Stockscreener 앱 받기
7.04
3.56%
-0.26
전일 마감가:
$7.30
열려 있는:
$7.35
하루 거래량:
2.93M
Relative Volume:
0.78
시가총액:
$552.24M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-2.2278
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
-12.33%
1개월 성능:
-26.74%
6개월 성능:
-44.26%
1년 성능:
-32.05%
1일 변동 폭
$7.02
$7.48
1주일 범위
$7.01
$8.44
52주 변동 폭
$2.68
$14.80
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
REPL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
7.04 | 572.64M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-10-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-09-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Aug Analyst Calls: Is now the right time to enter Replimune Group IncQuarterly Profit Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Replimune Group (NASDAQ:REPL) Trading Down 5.4%Should You Sell? - MarketBeat
Replimune Highlights RP1, RP2 Progress Ahead of JPM Conference - TipRanks
Replimune Group, Inc. Updates on RP1 and RP2 Programs - TradingView — Track All Markets
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-11 11:23:41 - Улправда
Why Replimune Group Inc. stock remains a top recommendationNew Releases Roundup & HOKA model picks for your routine - ulpravda.ru
Why Replimune Group Inc. stock is seen as undervaluedCPI Data & Consistent Return Investment Signals - Улправда
How institutional buying supports Replimune Group Inc. stock - ulpravda.ru
Replimune Group (NASDAQ:REPL) Shares Up 10.9%Should You Buy? - MarketBeat
Will Replimune Group Inc. stock reach all time highs in 20252026 world cup usa national team qualification star players possession football winner prediction expert opinion - ulpravda.ru
Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL) - MarketBeat
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - 富途牛牛
HC Wainwright & Co. Upgrades Replimune Group (REPL) - MSN
Replimune Group (NASDAQ:REPL) Shares Down 6.4%What's Next? - MarketBeat
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months - MSN
Replimune announces priority review for its melanoma treatment - MSN
Replimune Group (NASDAQ:REPL) Trading Up 4.8%Should You Buy? - MarketBeat
Replimune Group Inc (HAM:7R8) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Replimune Group Inc. stock overvalued by current metricsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
How Replimune Group Inc. stock trades during market volatility2025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Why Replimune Group Inc. stock could benefit from AI revolution2025 Fundamental Recap & Weekly Return Optimization Alerts - Улправда
Is Replimune Group Inc. stock supported by strong fundamentalsJuly 2025 Setups & Smart Swing Trading Alerts - Улправда
Why hedge funds are buying Replimune Group Inc. stock2025 Dividend Review & Free Reliable Trade Execution Plans - DonanımHaber
Aug Catalysts: Why Replimune Group Inc. stock remains a top recommendation - Улправда
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - TMX Newsfile
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech pioneering oncolytic immunotherapies to speak at J.P. Morgan - Stock Titan
Replimune Shares Face Mounting Headwinds - AD HOC NEWS
Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential Weakness - simplywall.st
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Replimune Group earns relative strength rating upgrade; hits key benchmark - MSN
What analysts say about Replimune Group Inc stockVolume Spike Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Replimune Group, Inc. $REPL Holdings Trimmed by Braidwell LP - MarketBeat
Replimune Group (NASDAQ:REPL) Director Kapil Dhingra Sells 3,169 Shares - MarketBeat
Replimune Group, Inc. $REPL Shares Sold by Redmile Group LLC - MarketBeat
Replimune Group Director Kapil Dhingra Sells All Shares - TradingView — Track All Markets
[Form 4] Replimune Group, Inc. Insider Trading Activity - Stock Titan
Replimune Group, Inc. $REPL Shares Sold by Marshall Wace LLP - MarketBeat
Nan Fung Group Holdings Ltd Lowers Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 - Nasdaq
Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 10,000 Shares of Stock - MarketBeat
Replimune Stock Presents a Complex Investment Narrative - AD HOC NEWS
Saturn V Capital Management LP Takes $1.20 Million Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group CEO Sushil Patel Sells 10,000 Shares - TradingView
CEO Patel Sells 10,000 ($111.3K) Of Replimune Group Inc [REPL] - TradingView
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Investors - The National Law Review
Levi & Korsinsky Helps Retail Investors SueWallSt Over Alleged Fraud by Replimune Group, Inc. - The National Law Review
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma DrugHagens Berman (PR Newswire) - Aktiellt
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dhingra Kapil | Director |
Dec 09 '25 |
Sale |
10.40 |
3,169 |
32,958 |
0 |
4.73%
0.92%
자본화:
|
볼륨(24시간):